Danni Hewson, head of financial analysis at AJ Bell, said: “There was good news on tariffs for the UK, with a deal struck to maintain the current zero tariffs on pharmaceutical exports.
“But there was little market reaction, with GSK up a fraction and AstraZeneca ending the day down a touch.
“Both companies have already announced multi-billion pound investments into the US – something investors had anticipated would give them favourable treatment from a president focused on US manufacturing capabilities.”
Contact details are available to account holders.
Create a free account to get in touch with this expert.